B
Bullisch
Bullisch · 25%TXG
$7.67
Szenariopreis
$73.020
+1.497 (+2.05%)Zum Schluss
Loading chart…
- Hoch
- 74.450
- Eröffnung
- 70.810
- Volumengewichteter Durchschnittskurs
- 72.76
- Volumen
- 1.41M
- Marktkap.
- 2.38B
- Tief
- 70.810
- Umsatz
- 102.82M
- EV/EBITDA, TTM
- -8.95
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.
Bewertungskennzahlen
Das aktuelle erwartete KGV von 10X Genomics Inc (TXG) beträgt -9.54, verglichen mit dem 5-Jahres-Durchschnitt von -45.79.
Alphio-AI-Kursszenarien für TXG
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die TXG halten
Event-Zeitleiste
News
9.510-24CNBCBiotech Sector Recovery: Moderna Leads the Charge
9.510-17stocktwitsAnalysis of Ark's Portfolio Performance in Q3
9.510-13PRnewswire10x Genomics to Report Q3 Financial Results on November 5, 2026
2.010-12FoolHealthcare Stocks Outperform Magnificent Seven
7.510-07PRnewswire10x Genomics Partners with Fred Hutch to Advance Cancer Research
TXG FAQ – beantwortet von Alphio AI
10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).
Community
Mehr ↗
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.